<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Chapurlat, Roland</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Odanacatib in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-21</style></pages><abstract><style  face="normal" font="default" size="100%">Odanacatib is a selective, potent, and reversible cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This article discusses results of A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK0822) in Postmenopausal Women Previously Treated with Alendronate. The trial found odanacatib to be safe and effective for increasing bone mineral density in postmenopausal women previously treated with alendronate.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>